T
Thasia G. Woodworth
Researcher at University of California, Los Angeles
Publications - 82
Citations - 9035
Thasia G. Woodworth is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Rheumatoid arthritis & Tocilizumab. The author has an hindex of 35, co-authored 80 publications receiving 8296 citations. Previous affiliations of Thasia G. Woodworth include University of the West of England & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S Smolen,André D. Beaulieu,Andrea Rubbert-Roth,Cesar Ramos-Remus,Josef Rovensky,Emma Alecock,Thasia G. Woodworth,Rieke Alten +7 more
TL;DR: Tocilizumab could be an effective therapeutic approach in patients with moderate to severe active rheumatoid arthritis.
Journal ArticleDOI
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Mark C. Genovese,James D. McKay,Evgeny Nasonov,Eduardo Mysler,Nilzio Antônio da Silva,Emma Alecock,Thasia G. Woodworth,Juan J. Gomez-Reino +7 more
TL;DR: Tocilizumab combined with any of the DMARDs evaluated was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents.
Journal ArticleDOI
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
Graeme Jones,Anthony Sebba,Jieruo Gu,Mitchell B. Lowenstein,Armando Calvo,Juan J. Gomez-Reino,Daniel Siri,Matija Tomšič,Emma Alecock,Thasia G. Woodworth,Mark C. Genovese +10 more
TL;DR: Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotRexate or biological agents has not previously failed.
Journal ArticleDOI
OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
T. Pham,D. van der Heijde,Roy D. Altman,Jennifer J. Anderson,Nicholas Bellamy,Marc C. Hochberg,Lee S. Simon,Vibeke Strand,Thasia G. Woodworth,Maxime Dougados +9 more
TL;DR: This data driven and experts' opinion approach is the basis for proposing an optimal simplified set of responder criteria for OA clinical trials.
Journal ArticleDOI
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Paul S. Changelian,Mark Edward Flanagan,Douglas J. Ball,Craig R. Kent,Kelly S. Magnuson,William H. Martin,Bonnie J. Rizzuti,Perry S. Sawyer,Bret D. Perry,William H. Brissette,Sandra P. McCurdy,Kudlacz Elizabeth M,Maryrose J. Conklyn,Eileen A. Elliott,Erika R. Koslov,Michael B. Fisher,Timothy J. Strelevitz,Kwansik Yoon,David A. Whipple,Jianmin Sun,Michael John Munchhof,John L. Doty,Jeffrey M. Casavant,Todd Andrew Blumenkopf,Michael Hines,Matthew Frank Brown,Brett M. Lillie,Chakrapani Subramanyam,Chang Shang-Poa,Anthony J. Milici,Gretchen E Beckius,James D. Moyer,Chunyan Su,Thasia G. Woodworth,Anderson See Gaweco,Chan R. Beals,Bruce H. Littman,Douglas A. Fisher,James F. Smith,Panayiotis Zagouras,Holly A. Magna,Mary Josephine Saltarelli,Johnson Kimberly Sue,Linda F. Nelms,Shelley G. des Etages,Lisa S. Hayes,Thomas T. Kawabata,Deborah Finco-Kent,Deanna L. Baker,Michael J Larson,Ming-Sing Si,Ricardo T. Paniagua,John P. Higgins,Bari Holm,Bruce A. Reitz,Yong Jie Zhou,Randall E. Morris,John J. O'Shea,Dominic C. Borie +58 more
TL;DR: It is believed JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clinical settings.